je.st
news
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck
2014-01-13 07:51:19| Biotech - Topix.net
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today the acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. , comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.
Tags: assets
therapeutic
acquires
merck
Category:Biotechnology and Pharmaceuticals